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Abstract
Background: Recent evidence indicates that disrupted sleep could contribute to the development of Alzheimer’s
disease by influencing the production and/or clearance of the amyloid-β protein. We set up a case-control study to
investigate the association between long-term work-induced sleep disruption, cognitive function, and brain
amyloid-β burden.
Methods: Nineteen male maritime pilots (aged 48–60 years) with chronic work-related sleep disruption and a sex-,
age-, and education-matched control sample (n = 16, aged 50–60 years) with normal sleep completed the study.
Primary sleep disorders were ruled out with in-lab polysomnography. Additional sleep measurements were
obtained at home using actigraphy, sleep-wake logs, and a single-lead EEG device. Cognitive function was assessed
with a neuropsychological test battery, sensitive to early symptomatic Alzheimer’s disease. Brain amyloid-β burden
was assessed in maritime pilots using 18F-flutemetamol amyloid PET-CT.
Results: Maritime pilots reported significantly worse sleep quality (Pittsburgh Sleep Quality Index (PSQI) = 8.8 ± 2.9)
during work weeks, compared to controls (PSQI = 3.2 ± 1.4; 95% CI 0.01 to 2.57; p = 0.049). This was confirmed with
actigraphy-based sleep efficiency (86% ± 3.8 vs. 89.3% ± 4.3; 95% CI 0.43 to 6.03; p = 0.03). Home-EEG recordings
showed less total sleep time (TST) and deep sleep time (DST) during work weeks compared to rest weeks (TST
318.56 (250.21–352.93) vs. TST 406.17 (340–425.98); p = 0.001; DST 36.75 (32.30–58.58) vs. DST 51.34 (48.37–69.30);
p = 0.005)). There were no differences in any of the cognitive domains between the groups. For brain amyloid-β
levels, mean global cortical standard uptake value ratios of 18F-flutemetamol were all in the normal range
(1.009 ± 0.059; 95% CI 0.980 to 1.037), confirmed by visual reads.
Conclusions: Capitalizing on the particular work-rest schedule of maritime pilots, this study with a small sample
size observed that long-term intermittent sleep disruption had no effects on global brain amyloid-β levels or
cognitive function.
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Background
Sleep loss has been associated with increased risk of de-
mentia in later life, specifically dementia caused by Alz-
heimer’s disease (AD). In a meta-analysis of 27 studies
with nearly 70.000 participants, sleep loss—mostly de-
fined as self-reported sleep of < 6 h per night—carried an
average relative risk of 1.68 (95% CI 1.45 to 1.86) of de-
veloping dementia caused by AD [1]. This finding is
relevant, because the etiology of late-onset AD remains
unknown and therapeutic options are limited, making
sleep a potential target for prevention or treatment of
AD [2, 3]. The association between sleep loss and AD
could be explained by reverse causality, wherein sleep
loss is an early, preclinical manifestation of Alzheimer’s
pathology [4–6]. However, the association may also be
causal, wherein sleep loss contributes to the develop-
ment of the disease. The latter hypothesis is based on a
small number of animal and human studies that have
identified mechanisms that could explain how sleep loss
may increase the risk of AD. In mouse models of genetic
and sporadic AD, for example, sleep loss increased brain
amyloid-β accumulation [7–10]. In humans, we have
previously showed that a single night of full sleep
deprivation impaired the overnight reduction in CSF
amyloid-β, causing 10% higher levels of CSF amyloid-β
the next morning [11]. Also in humans, selective disrup-
tion of slow wave sleep (SWS), without affecting other
sleep stages, led to a comparable overnight difference in
CSF amyloid-β [12]. Additionally, acute increases (5%) in
PET-amyloid-β levels in the hippocampus and thalamus
were observed after a single night of full sleep
deprivation [13]. Two mechanisms have been proposed
to explain the relationship between sleep loss and
amyloid-β accumulation. First, the clearance of soluble
toxic waste (including amyloid-β) from the central ner-
vous system, characterized by exchange of interstitial
and cerebrospinal fluids through the glymphatic path-
way, appears more effective during sleep than in wake-
fulness [14–18]. Second, the production of amyloid-β
may be increased during wakefulness and reduced dur-
ing sleep (especially SWS) [5, 11, 17, 19, 20]. These find-
ings have led to the hypothesis that long-term sleep loss,
through repetitive episodes of amyloid-β accumulation,
may contribute to AD. However, evidence from human
studies is lacking, and it remains unknown which quan-
tity of sleep loss, both in terms of duration and intensity,
would be required to raise the risk of developing demen-
tia due to AD.
The unique work of maritime pilots in the
Netherlands offers an opportunity to study the associ-
ation between long-term sleep disruption and AD risk.
Maritime pilots have a work schedule characterized by
one week of irregular and unpredictable working hours,
leading to reduced and fragmented sleep, followed by a
rest week with unrestricted sleep. Their sleep disruptions
are caused by external, occupational factors, which re-
duce the bias of intrinsically caused sleep problems that
could represent an early symptom preceding the clinical
manifestation of dementia due to AD (i.e., reverse caus-
ality). In this group of maritime pilots, we sought to ex-
plore the effects of long-term, externally induced sleep
disruption on cognitive function and brain amyloid-β
burden, as biomarker of AD.
Methods
Study design
The SCHIP study (Sleep Cognition Hypothesis In mari-
time Pilots) is a case-control study in healthy volunteers
under the hypothesis that repeated nights of sleep loss
may contribute to the risk of dementia due to AD by
gradually increasing amyloid-β levels. The study took
place between December 2016 and May 2019 and was
conducted and reported according to the STROBE
guidelines for case-control studies. The timing between
measurements was consistent across all participants.
Sample size calculations were performed using G*power
[21] and published previously [22]. The study protocol
was peer-reviewed and published in BMJ Open [22].
Study population
We included 19 middle-aged (mean age = 53; age range:
48 to 60 years) men from the national organization of
Dutch maritime pilots (Nederlandse Loodswezen). The
profession of maritime pilots in the Netherlands is
almost exclusively (99%) male. Their profession is char-
acterized by sleep disruptions caused by external,
occupational factors, wherein every other week is char-
acterized by sleep disruption. We recruited maritime pi-
lots with a work history of an average of 20 years
(mean = 19.8; range 10 to 30 years). Details of the study
population and their occupation have been described in
our methods paper [22] and can be found in the add-
itional information file (see Additional file 1).
Maritime pilots were compared to age-, sex-, and
education-matched healthy volunteers (n = 16; mean
age = 57; age range 51 to 62 years) with occupations
comparable in intellectual demand, but with regular
working hours (no shift work). Control participants had
normal sleep, confirmed by a Pittsburg Sleep Quality
Index (PSQI) of < 5 as well as regular bed times (be-
tween 8 p.m. and midnight), and regular wake-up times
(between 5 a.m. and 9 a.m.). Participants were excluded
from taking part in the study if they were using neuroac-
tive medications, consumed > 30 alcoholic beverages per
week, had a body mass index of > 30 kg/m2, suffered
from intrinsic sleeping disorders (i.e., insomnia, REM
sleep behavioral disorder; ruled out by PSG) or, for con-
trols only, if they had self-reported cognitive complaints
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(indicated by Cognitive Failure Questionnaire (CFQ) and
general health questionnaire). Vascular health was
assessed during study visits, using a history of health-
related events, i.e., high cholesterol, smoking, diabetes,
and hypertension in addition to blood pressure measure-
ments in maritime pilots. Baseline characteristics are
listed in Table 1; Fig. 1 provides a study flow chart.
Ethical approval
The SCHIP study was approved by the institutional re-
view board (CMO Region Arnhem-Nijmegen,
NL55712.091.16, file number 2016-2337) and performed
in accordance with good clinical practice guidelines and
the world medical associations code of ethics (Declar-
ation of Helsinki). Written informed consent was ob-
tained from all participants after they received detailed
study information. Participants received a stipend of 50
euros for participating, travel costs were compensated.
Sleep measurements
We combined several complementary methods to assess
sleep quality.
PSQI
PSQI was filled in twice by maritime pilots (work and
rest week) and once by controls.
Actigraphy and sleep log
Accelerometer-based sleep measurements (Actiwatch 2;
Philips Respironics, Eindhoven, The Netherlands) in
maritime pilots and controls were collected for a period
of 10 consecutive days. Data was validated with sleep-
wake diaries. For maritime pilots, these days contained a
mixture of work and rest days. Measurements were
taken during the screening phase of the study (Fig. 1),
before cognitive testing and amyloid PET scans.
Polysomnography (2016/2017)
To ascertain that neither maritime pilots nor controls
had intrinsic sleep disorders, we performed full polysom-
nography (PSG) in a sleep lab (Kempenhaeghe, Heeze,
The Netherlands), registering total sleep time (TST),
sleep stages (N1, N2, N3, REM), wake time after sleep
onset (WASO), sleep efficiency (SEF), and sleep onset la-
tency (SOL). The PSG took place on Sunday nights dur-
ing rest weeks for maritime pilots and normal weekend
days for controls, between 2016 and 2017 (Fig. 1).
Home-EEG (2019)
We performed objective measurements of sleep quality
during work and rest weeks in 13 of the 19 maritime pi-
lots. For this, we used a novel and innovative device with
a dry, single-lead EEG electrode (SmartSleep; Philips,
Eindhoven, The Netherlands) [23]. This device is a
headband that records EEG signals and can differentiate
between light and deep sleep. Furthermore, it measures
total sleep time (TST), sleep onset latency (SOL), num-
ber of short awakenings (< 5 min awake), and number of
arousals (> 5 min awake). Maritime pilots were
instructed to wear the headband for 20 consecutive days
(10 workdays and 10 rest days). These measurements
took place in 2019, before the amyloid PET scan (Fig. 1).
Cognitive assessment
The aim of the cognitive assessment was to explore ef-
fects of long-term exposure to sleep disruption in mari-
time pilots on AD-related cognitive impairment.
Therefore, we applied a cognitive test battery that was
designed to detect cognitive dysfunction in preclinical
AD [24]. Tests focused on episodic memory (Logical
Memory Subtest from the Wechsler Memory Scale –
Fourth Edition (WMS-IV LM), Rey Auditory Verbal
Learning Test (RAVLT)), semantic memory and lan-
guage (letter and semantic fluency, Boston Naming
Test), working memory and executive function (Digit
Span subtest from the Wechsler Adult Intelligence Scale
– Fourth Edition (WAIS-IV), Trail Making Test (TMT)
parts A and B, WAIS-IV Coding), and attention (Test of
Attentional Performance 2.0, TAP). Overnight memory
consolidation was assessed using a novel paradigm based
on the Doors Test [25], assessing visual recognition
memory after short delay (10 min) and memory consoli-
dation after long delay (after sleep). An overview about
the cognitive tasks is summarized in the additional infor-
mation file (see Additional file 2) and described in detail
in our methods paper [22]. Cognitive tests were per-
formed in the morning following PSG (in 2016 and
2017).
Amyloid PET-CT imaging with 18F-flutemetamol
Brain PET-CT scans were acquired in 2019 (Fig. 1) in
maritime pilots only, since outcomes can be compared
to normative data from the literature. We used the vali-
dated tracer 18F-flutemetamol [26], a tracer that
performs comparable to 11C-PIB [27]. Previous studies
suggested that CSF and PET measurements of amyloid-β
are in high concordance [28–31], while some suggest
that PET is more powerful and more specific to AD
pathology [32, 33]. Static brain images were acquired
90–110 min post-injection (four frames of 5 min) after
bolus injection of approximately 185MBq 18F-flutemeta-
mol on a Siemens Biograph mCT. To measure tissue up-
take ratios, PET scans of the PET-CT session were
registered to the CT scan of the PET-CT session by rigid
body linear registration with nearest neighbor
interpolation using FSL’s FLIRT (FMRIB’s Linear Image
Registration Tool) [34–36]. CT scans were then
registered to the MNI152 2mm skull template by affine
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linear registration with a mutual information cost func-
tion and nearest neighbor interpolation using FSL’s FLIR
T and by non-linear registration using FSL’s FNIRT
(FMRIB’s Non-linear Registration Tool) [34, 35]. These
transformations were combined to align the PET scan to
the MNI152 space in one single step. Tissue ratio was
used as outcome measure, which is equivalent to the
standard uptake value ratio (SUVR). The global cortical
areas as well as prefrontal and temporal cortex and the
cerebellum were selected with the MNI152 2 mm cor-
tical atlas. Subsequently mean uptake values of these
regions of interest (ROIs) and the tissue ratio, equiva-
lent to the SUVR, were calculated using the
cerebellum as reference region [37, 38]. Normal global
SUVR in a cognitively healthy population (aged 30–
60) was 1.3 (± 0.09) [27], comparable to mean SUVR
of 1.29 (± 0.2) reported by Thurfjell et al. [39]. As
additional step, all scans were visually rated as posi-
tive/negative for the presence of amyloid-β deposition
by an experienced and trained [40] nuclear medicine
physician (JB) using validated criteria [37].
In the original protocol, an additional MRI scan was
planned for PET-MRI co-registration to allow more de-
tailed regional analyses of amyloid-β uptake [22]. Be-
cause of limitations in funding, this could not be
performed for this study after all.
Fig. 1 Flow diagram SCHIP study. Abbreviations: PSQI, Pittsburgh Sleep Quality Index; CFQ, Cognitive Failure Questionnaire; HADS, Hospital
Anxiety and Depression Scale; TAP, Test of Attentional Performance; RBD, REM sleep behavior disorder; PSG, polysomnography. Superscript letter
“a” indicates that over the course of the study, four maritime pilots went into retirement; therefore, analysis for the work days is based on the
remaining, employed maritime pilots (n = 13)
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Statistical analysis
Statistical analyses were performed using IBM SPSS Sta-
tistics for Windows, version 20.0 (IBM Corp., Armonk,
NY, USA). Alpha was set at 0.05 and tested two-sided.
All continuous variables were assessed for normal
distribution by inspection of histograms and the
Shapiro-Wilk test. Normally distributed data are shown
as mean ± SD. Not normally distributed data are pre-
sented with median and interquartile ranges (IQR). For
primary outcomes of cognitive assessment, raw test
scores were transformed into z-scores for each neuro-
psychological test. Z-scores were computed in SPSS and
were based on mean and SD of the whole sample. For
the other primary outcome measure, amyloid-β burden,
we used the mean global standard value uptake ratio
(SUVR) and the dichotomous visual read of the amyloid
PET scans (positive/negative) [37]. An independent sam-
ples t-test was performed to compare normally distrib-
uted outcome measures between the groups (shown as
mean ± SD); not normally distributed outcome measures
were assessed with Mann-Whitney U tests (shown as
median (IQR)). With regard to the home-EEG data, a
Wilcoxon signed rank test was performed to compare
deep sleep time (DST) during work weeks to DST dur-
ing rest periods.
Results
After exclusion and drop-out of participants (see Fig. 1),
19 maritime pilots and 16 controls completed the study
(Fig. 1, Table 1).
Maritime pilots were on average 4 years younger than
controls (Table 1; 95% CI − 6.139 to − 1.716). Results
from the independent t-test did not indicate other
differences between the groups at baseline (Table 1). All
participants were Dutch, of white European descent, and
had the same level of education.
Sleep characteristics
PSQI
Maritime pilots reported worse sleep quality on the
PSQI compared to controls, during rest weeks but espe-
cially during work weeks (Table 2). When comparing
PSQI scores between work week and rest week within
maritime pilots, results of the t-test revealed that the
average PSQI score for work weeks was almost twice the
score for rest weeks, with values exceeding the validated
cutoff point (≥ 7) for abnormal sleep behavior (Table 2).
Actigraphy
Subjective reports (PSQI) of poor sleep was confirmed
by data from 10 days of actigraphy (mix of workdays and
rest days), which indicated more awakenings and less
sleep efficiency in the maritime pilot group compared to
controls (Table 2).
PSG (2016/2017)
Both maritime pilots and controls had normal sleep pat-
terns, including normal amount of DST (Table 2), ruling
out intrinsic sleep disorders and indicating undisturbed
sleep in maritime pilots during rest days.
Home-EEG (2019)
We were able to analyze EEG-based sleep measurements
during work and rest days in 13 maritime pilots (of the
n = 19 maritime pilots, 4 had retired by 2019 when these
measurements were scheduled, and could therefore no
longer be measured during workdays; 2 could not be an-
alyzed due to technical issues) (Fig. 1). Maritime pilots
showed less TST during work weeks compared to rest
weeks (Z = − 3.18; p = 0.001) as well as less DST during
work weeks compared to rest weeks (Z = − 2.83; p =
0.005) (Table 3). Based on the home-EEG measure-
ments, we created hypnograms of one maritime pilot for
a work week and a rest week, illustrated in Fig. 2.
Cognitive assessment
For cognitive assessment, we transformed all raw neuro-
psychological test scores into z-scores. Results from the
independent t-test did not indicate differences between
maritime pilots and controls on tests of episodic mem-
ory (WMS-IV LM recognition, RAVLT total median).
Small differences were observed on semantic memory
and language, in which maritime pilots performed
slightly better on the Boston Naming Test compared to
controls. Performance on working memory and execu-
tive function (WAIS-IV, TMT, WAIS-IV Coding) and
attention (TAP 2.0) did not differ significantly between
Table 1 Baseline characteristics
Characteristics Controls, n = 16 Maritime pilots, n = 19
Age, years 57 ± 2.9 53 ± 3.4
Educational attainment, years 17.4 ± 7.3 18 ± 0
BMI, kg/m2 25.5 ± 2.7 25.7 ± 2.7
History of diabetes 0 (0) 0 (0)
SBP, mmHg NA 148.0 ± 16.4
DBP, mmHg NA 90.16 ± 11.7
Medication (“yes/no”) 2 (10.5) 4 (21.1)
Smoking (“yes/no”) 3 (15.8) 3 (15.8)
History of hypertension 0 (0) 0 (0)
History of high cholesterol 0 (0) 1 (5.3)
CFQ 26.4 ± 10.8 29 ± 7.8
HADS Anxiety 4.8 ± 3 4.0 ± 1.7
HADS Depression 3.6 ± 2.5 3.7 ± 2.7
Data is shown as mean ± SD or no. (%) (for normally distributed data)
Abbreviations: BMI body mass index, SBP systolic blood pressure, DBP diastolic
blood pressure, CFQ Cognitive Failure Questionnaire, HADS Hospital Anxiety
and Depression Scale, NA not applicable
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the groups. Maritime pilots performed slightly better on
the visual recognition memory after short delay com-
pared to controls. Long-term memory consolidation,
however, did not differ between the groups. All test
scores were within normal age- and education-adjusted
ranges based on available normative data (data not
shown). All results can be found in Table 4.
18F-flutemetamol PET-CT
Amyloid PET scans were administered in maritime pi-
lots only (n = 19, Fig. 1). SUVRs in healthy populations
were reported as 1.29 (± 0.2) [39] and 1.3 (± 0.09) [27].
The global cortical SUVR in maritime pilots was 1.009
(± 0.059; 95% CI 0.980 to 1.037) and therefore below
normal values for a cognitively healthy population in this
age range [27, 39]. More specifically, we detected a
SUVR of 0.860 (± 0.098; 95% CI 0.813 to 0.907) for
frontal lobes and a SUVR of 0.996 (± 0.06; 95% CI 0.967
to 1.025) for temporal lobes. In addition, all scans were
rated negative for the presence of amyloid-β depos-
ition on visual reading. Figure 3 shows examples of
amyloid PET images from two representative
participants. There were no correlations between
SUVRs and sleep quality (PSQI overall score and DST
(for rest and work weeks)).
Discussion
We investigated global brain amyloid-β levels and cogni-
tive function in a unique population experiencing long-
term sleep disruption, wherein every other week was
characterized by sleep disruption due to irregular work-
ing hours.
Our main finding is that, in this relatively small, but
deeply phenotyped sample, this intensity and pattern of
sleep disruption was not associated with elevated brain
amyloid-β levels, nor with cognitive decline.
In previous studies, a single night of full sleep
deprivation, or selective restriction of deep sleep,
and chronic partial sleep fragmentation (rodents
only) increased brain amyloid-β levels [8–13]. These
observations have fueled the hypothesis that re-
peated nights of sleep loss may contribute to the
risk of dementia due to AD by gradually increasing
amyloid-β levels.
Table 2 Comprehensive sleep characteristics of maritime pilots and controls
Measures Controls, n = 16 Maritime pilots, n = 19 p value
PSG TST, min 406 ± 44 403 ± 51 0.86
N1, min 46 ± 18 41 ± 14 0.40
N2, min 232 ± 36 215 ± 36 0.20
DST, min 50 ± 25 66 ± 28 0.10
REM, min 68 ± 17 79 ± 17 0.10
WASO, min 61 ± 26 53 ± 39 0.48
SEF, % 85.8 ± 7.1 86.1 ± 9.4 0.91
SOL, min 8 ± 7 11 ± 9 0.32
Actiwatch No. awakenings 33.5 ± 11.1 37.8 ± 10.3 0.24
SEF, % 89.3 ± 4.3 86 ± 3.8 0.03*
PSQI (rest week vs. control Overall score 3.2 ± 1.4 4.5 ± 2.2* 0.049*
PSQI (work week vs. control) Overall score 3.2 ± 1.4 8.8 ± 2.9** < 0.001**
Data is shown as mean ± SD (for normally distributed data)
Actiwatch data and PSQI were collected in 2016 and 2017. Actiwatch data was collected for a period of 10 consecutive days; for maritime pilots, these 10 days
were a mix of work and rest days. PSQI was administered twice for maritime pilots, including one work week and one rest week
Abbreviations: PSG polysomnography, TST total sleep time, DST deep sleep time, REM rapid eye movement sleep, WASO wake after sleep onset, SEF sleep
efficiency, SOL sleep onset latency, PSQI Pittsburgh Sleep Quality Index
*Significant at p <0 .05
**Significant at p < 0.001
Table 3 Results from the home-EEG measurements (maritime pilots only)
Measures Rest week, n = 13 Work week, n = 13 p value
Home EEG TST†, min 406.17 (340–425.98) 318.56 (250.21–352.93) 0.001*
DST†, min 51.34 (48.37–69.30) 36.75 (32.30–58.58) 0.005*
Data is shown as median (IQR) (for not normally distributed data)
Home-EEG recordings were performed in 2019 in maritime pilots only using a dry single-lead EEG device (Philips, Eindhoven, The Netherlands)
Abbreviations: TST total sleep time, DST deep sleep time
*Significant at p < 0.05
†Means calculated based on sleep periods within work week or rest week respectively
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Fig. 2 Example of a maritime pilots’ sleep schedule. a Hypnogram is based on 7 consecutive working days of sleep measurements with a dry
electrode single-lead home-EEG device. b Hypnogram is based on 7 rest days of sleep measurements with a dry electrode single-lead
home-EEG device
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The sample of maritime pilots offered a unique oppor-
tunity to explore if long-term, externally induced sleep
disruptions increase dementia risk in terms of AD-
related impaired cognitive function and amyloid-β
burden. Their sleep behavior is characterized by work
weeks with disrupted sleep, alternating with rest weeks
of unrestricted sleep. This pattern was confirmed using
a combination of methods: self-reported disrupted sleep
during work weeks was objectified by sleep diaries, acti-
graphy, and home-EEG measurements. Relatively normal
sleep during rest weeks of maritime pilots was further-
more confirmed with PSG (compared to controls) and
home-EEG measurements. Moreover, using PSG we
were able to exclude intrinsic sleep disorders in this
group, which is important because sleep loss may be an
early manifestation of Alzheimer’s pathology and could
lead to a reverse causality association [41, 42]. To
explore possible AD-related impaired cognitive perform-
ance, we applied a cognitive test battery that was chosen
for its sensitivity to cognitive changes in early, preclinical
AD [24]. On all cognitive domains, maritime pilots
showed normal cognitive performance, compared not
only to the control group, but also to normative values.
This was also the case for overnight episodic memory
consolidation, which is dependent on deep sleep [5, 43].
We considered that normal cognitive function would
not rule out increased amyloid-β levels, since early
stages of amyloid-β accumulation (indicated by PET or
CSF) can have a long asymptomatic stage. Therefore, we
performed additional global brain amyloid-β imaging in
maritime pilots. None of the maritime pilots had evi-
dence of elevated amyloid-β levels, with SUVR values
remaining below the values established for a healthy
population [27, 39]. In a recent meta-analysis, the
Table 4 Results of cognitive assessment and memory consolidation
Measures Controls, n = 16 Maritime pilots, n = 19 p value
WMS-IV LM I 0.16 ± 1.07 − 0.08 ± 0.99 0.49
LM II 0.29 (− 0.93–1.01) 0.11 (− 0.61–0.83) 0.72
LM recognition 0.25 ± 1.10 − 0.12 ± 0.94 0.29
RAVLT Total − 0.08 (− 0.63–0.61) 0.77 (− 1.14–1.09) 0.41
Del. recall − 0.08 ± 0.76 0.06 ± 1.25 0.70
Del. recognition − 0.10 ± 1.15 0.21 ± 0.85 0.37
Sensitivity A’ 0.07 (− 0.85–0.82) 0.22 (− 0.30–0.82) 0.41
WAIS-IV Coding − 0.10 ± 0.59 0.21 ± 1.26 0.37
Digit span − 0.21 ± 0.62 0.23 ± 1.24 0.21
TMT Part A − 0.09 ± 0.75 − 0.06 ± 1.15 0.94
Part B − 0.33 (− 0.57–0.75) − 0.38 (− 0.96–0.50) 0.24
Fluency D-A-T 0.07 ± 0.89 − 0.29 ± 1.13 0.78
Animal 0.38 (− 0.88–0.73) 0.20 (− 0.70–0.91) 0.84
Profession − 0.26 ± 0.85 0.26 ± 1.13 0.14
BNT Short version − 0.11 (− 0.39–0.31) 0.20 (0.10–0.62) 0.02*
TAP evening Cued − 0.05 (− 0.72–0.44) − 0.39 (− 0.91–0.50) 0.37
Un-cued − 0.05 (− 0.87–0.89) − 0.17 (− 0.76–0.45) 0.84
TAP morning Cued − 0.10 (− 0.50–0.66) − 0.29 (− 0.71–0.12) 0.27
Un-cued − 0.13 (− 0.63–1.09) − 0.40 (− 0.74–0.33) 0.22
Visual recognition—short delay (10 min) Sensitivity, A’ − 0.27 ± 0.90 0.46 ± 0.58 0.007*
Hits − 0.33 (− 1.18–0.15) 0.64 (0.15–0.64) 0.03*
False alarms 0.19 ± 1.06 − 0.27 ± 0.84 0.16
Memory consolidation—long delay (after sleep) Sensitivity, A′ − 0.08 ± 0.95 0.35 ± 0.73 0.14
Hits 0.50 (− 0.21–0.70) − 0.08 (− 0.69–0.54) 0.20
False alarms 0.15 ± 0.90 − 0.41 ± 0.76 0.06
Data is shown as mean ± SD (for normally distributed data) or median (IQR) (for not normally distributed data)
Test results are expressed in z-scores. TAP: z-scores are based on median reaction-time. Visual recognition—short-term: assessed approximately 10min after
targets were presented. Memory consolidation after long-term took place after one night of sleep (approximately 10 h)
Abbreviations: WMS Wechsler Memory Scale, LM logical memory, RAVLT Rey Auditory Verbal Learning Test, WAIS Wechsler Adult Intelligent Scale, TMT Trail Making
test, BNT Boston Naming Test, TAP Test of Attentional Performance
*Significant at p < 0.05
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estimated prevalence of PET amyloid-positivity in cogni-
tively healthy men aged 55–60 years was 13% (95% CI
10.3 to 16%) [44]. This indicates that our observation of a
prevalence of 0/19 confidently rules out elevated amyloid-
β levels, even considering the relatively small sample size.
What could explain the observed absence of elevated
amyloid-β levels or impaired cognitive function, despite
evidence of long-term sleep disruptions?
First, assuming that the hypothesis that sleep dis-
ruption may cause AD is correct, the alternating pat-
tern of a week with unrestricted sleep following a
week of disrupted sleep may be insufficient to cause
elevated brain amyloid-β levels. Either sleep disrup-
tion during ≈ 50% of nights for ≈ 20 years is insuffi-
cient to affect amyloid-β clearance/production or the
week of normal sleep following a week of sleep dis-
ruption provides compensatory reductions in brain
amyloid-β levels. This latter option would then sug-
gest that disrupted sleep is a modifiable risk factor
and that it may not be necessary to achieve full
normalization of sleep to reduce AD risk. Whether
this can be extrapolated to the general population is
uncertain however. The maritime pilots may, due to
their profession, be better able to compensate normal
sleep in their rest weeks. While most studies link re-
duced total sleep time (< 6 h) to increased AD risk [1,
20], other work suggests that the risk is specifically
linked to reduced deep sleep [12, 17]. The maritime
pilots had reduced total sleep time during work
weeks, but the home-EEG recordings indicate that
they still achieved an average of 37 min of deep sleep
per sleep period. Therefore, SWS may have been in-
sufficiently impaired to result in abnormal amyloid-β
levels. This argument is, however, not supported by
recent work demonstrating that a reduction in total
sleep time, but not SWS, determined the increase in
amyloid-β production [20].
Second, it is possible that sleep disruption alone is in-
sufficient to increase AD risk, but requires the presence
of other risk factors, such as impaired glucose metabol-
ism [45], oxidative stress [46], depression [47], or general
poor vascular health [48]. Our study population was
healthy and had a low vascular risk (Table 1).
Current research on this topic is still in its very early
stage, with limited evidence supporting a causal relation-
ship between sleep loss and risk of AD dementia. The
association between sleep loss and AD may be driven by
reverse causality (sleep loss as an early manifestation of
AD) or by a shared common pathway that causes sleep
loss and increases AD risk. There is also recent evidence
that found no association between sleep (subjective sleep
quality) and risk of dementia [49].
Previous evidence suggesting a link between sleep and
AD has been limited to a small number of studies in ro-
dents and humans, with variations in methodology and
study population selection. Furthermore, the human
studies focused on the relationship between poor sleep
for a short period of time (1 or 2 nights) and its effects
on amyloid-β (or tau), but have not studied actual devel-
opment of AD dementia.
Longitudinal studies are available but lack rigorous
assessment of sleep and biomarker evidence of AD.
Our study adds information on the long-term associ-
ation between poor sleep and AD, combining object-
ive sleep measures with established biomarkers for
AD.
Fig. 3 Representative transversal slides from 18F-flutemetamol PET scans of two participants. Scans were acquired 90–110min post-injection and
show normal subcortical nonspecific uptake in the brain
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Strengths and limitations
A strength of the study is the comprehensive assess-
ments of all outcome measures: cognitive function was
assessed with an extensive test battery sensitive to early,
preclinical symptoms of AD; sleep was assessed with
various measurements including self-reported but also
objectively measured sleep, implementing innovative
techniques for sleep assessments (home-EEG); sleep dis-
orders were ruled out using PSG; and PET-amyloid im-
aging was used as a validated AD biomarker. A further
strength is the unique cohort of maritime pilots, with
prolonged and consistent exposure to sleep loss related
to their work, making this a highly valuable population
that allowed us to explore poor sleep as isolated variable
in relationship with the risk of AD dementia.
Our study is limited by the small sample size. Home-EEG
measurements were available in 13 of the 19 maritime pi-
lots. However, outcomes of these sleep measurements con-
firmed observations of work-related disrupted sleep based
on PSQI, sleep-wake dairy and actigraphy data in the whole
sample, and added novel data on total and deep sleep time
during work weeks and rest weeks.
The uniqueness of the population may also cause bias.
Maritime pilots are healthy, have no cardiovascular risk,
and are physically active in their work, factors that may
reduce their AD risk. They may be resilient to the conse-
quences of sleep disruption, because they have success-
fully performed this work for > 10 years. One example of
such resilience could be their ability to achieve deep
sleep even under conditions of fragmented and restricted
total sleep during work weeks or their capacity to gener-
ate sufficient deep sleep during rest weeks.
Another limitation is that controls, although matched
for sex, age, education, and general health, might not
have been matched entirely with regard to personality,
resilience, physical activity, or cognitive skills/general
intelligence.
One could argue that the absence of tau measure-
ments is a limitation, as recent evidence now also sug-
gests that sleep affects tau in a similar manner as
amyloid-β [50]. We did not perform tau measurements
because the maritime pilots had no evidence of cognitive
impairment. Since tau pathology is strongly correlated
with cognitive decline [51–53], it is highly unlikely to
find evidence of tau accumulation in subjects with nor-
mal cognitive function, even more so when they are
amyloid-negative. A final limitation is that amyloid-β
status was not obtained from the controls. Instead, we
compared our outcomes to normative values from the
literature, which were acquired with additional MRI
measurements for co-registration of the amyloid PET-
CT scans. Since we used CT to identify global amyloid-β
instead of MRI, this difference in methodology has to be
kept in mind when interpreting our results.
Conclusions
In this study, we tested the hypothesis that prolonged
sleep loss increases the risk of dementia due to AD. We
found that a history of work-induced, long-term sleep
disruption was not associated with impairment in cogni-
tive function, nor with elevated global brain amyloid-β
levels, in a group of healthy, middle-aged men. Taking
into account the small sample size of our study, our re-
sults do not necessarily refute the hypothesis we
intended to test, but neither support it. It is possible that
amyloid-β accumulation during periods with sleep
disruption can be reduced in nights with normal sleep.
Alternatively, sleep loss may only increase AD risk in
combination with other factors. Finally, the association
between sleep loss and AD in epidemiological studies
may be driven by reverse causality. These and other hy-
potheses have to be tested in future studies.
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